Related Experiment Video
Updated: Jul 15, 2026
07:51
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
How will INVEST and other hypertension trials change clinical practice?
1Division of Cardiovascular Medicine, University of Florida, College of Medicine, Gainesville 32610, USA.
Clinical Cardiology
|November 20, 2001
Summary
Three large clinical trials involving over 81,000 patients provide insights into hypertension management. Despite influencing guidelines, physician awareness of current hypertension guidelines remains low.
Area of Science:
- Cardiology
- Clinical Trials
- Hypertension Management
Background:
- Hypertension is a major global health concern.
- Effective management strategies are crucial for preventing cardiovascular events.
- Large-scale clinical trials are essential for advancing hypertension treatment understanding.
Purpose of the Study:
- To summarize findings from three major international clinical trials on hypertension management.
- To assess the impact of these trials on clinical practice and physician awareness of guidelines.
Main Methods:
- Analysis of data from three large international clinical trials: INVEST, ALLHAT, and CONVINCE.
- Combined enrollment of 81,649 patients across 18 countries.
- Inclusion of patient demographics, comorbidities (diabetes, CAD), and treatment outcomes.
Main Results:
- Systolic blood pressure <140 mmHg achieved by 70% of non-diabetics and 66% of diabetics in INVEST.
- High prevalence of cardiovascular risk factors: 38% smokers, 25% history of MI/stroke, 52% dyslipidemia.
- Despite trial influence, a significant portion of primary care physicians (41%) were unfamiliar with JNC VI guidelines.
Conclusions:
- These trials offer valuable data for hypertension management and guideline development.
- Physician education on risk stratification and guideline-based treatment is critical.
- Bridging the gap between trial evidence and clinical practice is necessary for optimal patient care.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Hypertension I: Introduction
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:23Hypertension V: Nursing Management
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.